TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
February 10 2021 - 3:01PM
Business Wire
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an
underwritten public offering of its common stock. The Company has
granted the underwriter a 30-day option to purchase up to an
additional 15% of the number of shares of its common stock offered
in the offering. All of the shares in the offering are to be sold
by TherapeuticsMD.
Cantor Fitzgerald & Co. is acting as sole bookrunning
manager for the offering.
TherapeuticsMD intends to use the net proceeds from the offering
for commercialization of its three FDA-approved products, IMVEXXY®
(estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a
symptom of vulvar and vaginal atrophy due to menopause, BIJUVA®
(estradiol and progesterone) capsules, a hormone therapy
combination of bio-identical 17ß-estradiol and bio-identical
progesterone in a single, oral softgel capsule, for the treatment
of moderate-to-severe vasomotor symptoms due to menopause in women
with a uterus, and ANNOVERA® (segesterone acetate/ethinyl estradiol
vaginal system), the first and only annual patient-controlled,
procedure-free, reversible prescription contraceptive option for
women, including to maximize ANNOVERA’s consumer-focused
commercialization strategy. TherapeuticsMD additionally may use a
portion of the net proceeds from the offering to discharge certain
indebtedness currently outstanding under its financing agreement
and intends to use a net portion of the proceeds for working
capital and general corporate purposes.
TherapeuticsMD has filed a shelf registration statement on Form
S-3 with the Securities and Exchange Commission (the “SEC”) with
respect to the offering that became effective on May 5, 2020. A
preliminary prospectus supplement (including an accompanying
prospectus) relating to the offering will be filed with the SEC.
Before buying any shares of TherapeuticsMD’s common stock in the
offering, you should carefully read the preliminary prospectus
supplement and the accompanying prospectus, together with the
information incorporated by reference therein. These documents
contain important information that you should consider when making
your investment decision. TherapeuticsMD’s SEC filings are
available to the public from the SEC’s website at www.sec.gov. When
available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained by contacting Cantor Fitzgerald & Co., Attention:
Capital Markets, 499 Park Ave., 6th Floor, New York, New York
10022, or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The Company is
committed to advancing the health of women and championing
awareness of their healthcare issues.
Forward Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that TherapeuticsMD intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control,
that may cause actual results to differ materially, including the
risks and uncertainties associated with market conditions, the
satisfaction of customary closing conditions related to the
offering, risks and uncertainties associated with TherapeuticsMD’s
business and finances in general and other risks described in the
sections titled “Risk Factors” in TherapeuticsMD’s filings with the
SEC, including its most recent Annual Report on Form 10-K, the
preliminary prospectus supplement with respect to the offering and
other filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210210005925/en/
Investor Contact Nichol Ochsner Vice President Investor
Relations 561-961-1900 Ext. 2088 nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2024 to May 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From May 2023 to May 2024